QoL assessed by EORTC and in-house symptom scales at 6 months for patients on low- or high-dose IFN-alfa. The mean result at baseline prior to starting IFN-alfa is also given for comparison. The asterisk reflects a significant difference for the loss-of-appetite item (P < .01). (A) EORTC symptom scales. (B) In-house module.